Option chain shows key data for VYNE Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for VYNE Therapeutics.

VYNE Therapeutics (NASDAQ:VYNE) Stock, Option Chain

VYNE Therapeutics

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

ALVR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

IBIO

VYNE

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher In Q1

Small Cap

Movers

ATNF

BCEL

BTCS

CMND

FTFT

GBNH

OCTO

PAVM

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RDZN

RELL

SDIG

SPEC

TGAN

XCUR

Shares of  Richardson Electronics, Ltd.  (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted weaker-than-expected results for its second quarter.

Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket

Earnings

Eurozone

Commodities

Global

Intraday Update

ALZN

COMM

LMDX

MIRO

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday.

The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The S&amp;P 500 also rose, gaining, 1.23% to 4,167.91.

Dow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companies

VYNE Therapeutics Inc

WIIM

Hillenbrand shares are trading higher. Keybanc maintained an Overweight rating on the stock

Piper Sandler analyst Michael S. Lavery upgraded Campbell Soup Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) to Overweight from Neutral, <a target="_blank" href="https://www.benzinga.com/quote/CPB/analyst-ratings" rel="noreferrer noopener">raising the price forecast from $47 to $56.</a>
The analyst upgraded Campbell Soup due to improved long-term growth prospects from its Rao&#8217;s brand and better sales trends in the U.S. (excluding SOVO brands).
Despite better trends, the stock has had a 15% pullback since mid-September. The analyst sees this as a good buying opportunity.
Lower steel costs (down 25%) and secured contracts for 2025 further support growth.
The analyst raised 2025 and 2026 earnings per share (EPS) estimates slightly, from $3.20 to $3.21 and $3.37 to $3.38, respectively.
Per the analyst, the stock is considered well-positioned among large-cap food stocks.
Also Read:<a target="_blank" href="https://benzinga.com/trading-ideas/movers/24/11/41982273/whats-going-on-with-ford-motor-stock-today-4" rel="noreferrer noopener"> What&#8217;s Going On With Ford Motor Stock Today?</a>
Campbell Soup has agreed to sell its Noosa yogurt business for an undisclosed amount, with the deal expected to close in first quarter of 2025. The company acquired Noosa as part of its SOVO purchase in March 2024.
The analyst assumes the sale will be finalized on January 1, 2025, with proceeds of around $250 million.
Per the analyst, the divestiture is expected to reduce sales by approximately $177 million annually and will slightly lower F25 earnings per share (EPS) by $0.01.
However, this impact is expected to be more than offset by higher revenue growth expectations.
The analyst raised the 2025 EPS estimates from $3.20 to $3.21 and the 2026 EPS expectations from $3.37 to $3.38.
Price Action: CPB shares are trading higher by 1.16% to $44.79 at last check Thursday.
Photo via <a href="https://commons.wikimedia.org/wiki/File:Campbell_tomato_soup_cans.jpg">Wikimedia Commons</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine" target="_blank" rel="noreferrer noopener">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a></li>
</ul>

Analyst Color

Equities

Upgrades

Price Target

Analyst Ratings

General

Campbell Soup Rao's Brand Growth Strong And US Sales Trend Improving, Analyst Upgrades Stock

Goldman Sachs analyst Mark Delaney maintained a neutral rating on Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and raised the price target from&nbsp;$10&nbsp;to&nbsp;$12.
Following the market close on November 12, 2024, Rivian Automotive and Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) confirmed <a target="_blank" href="https://www.benzinga.com/24/11/41934150/rivian-shares-rise-13-in-pre-market-after-volkswagen-increases-planned-investment-to-58b" rel="noreferrer noopener">the official launch</a> of their 50-50 joint venture (JV), set to begin on November 13.
The JV will focus on advancing electrical and electronic (E/E) architecture technology, explicitly targeting electronic control units (ECUs), network infrastructure, and associated software.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41973754/bilibilis-q3-earnings-revenue-surges-26-record-user-growth-margins-improve-as-games-lead-the-way" rel="noreferrer noopener">Bilibili's Q3 Earnings: Revenue Surges As Games Lead the Way, Stock Buyback And More</a>
Both companies will continue to develop vehicles independently, excluding areas like battery technology, powertrains, and autonomous driving systems from the collaboration.
The JV plans to leverage Rivian's existing software and E/E architecture stack. Rivian's R2 model, slated for production in the first half of 2026, will be the first vehicle to utilize this platform, with Volkswagen expected to implement it in their vehicles by 2027. An initial demonstration model, a retrofitted VW vehicle showcasing Rivian's technology, has already been developed as part of this collaboration.
The JV agreement outlines an increased total investment of up to $5.8 billion by 2027, revised upward from the initial $5 billion. Rivian's Chief Software Officer, Wassym Bensaid, and Volkswagen's Chief Technology Engineer, Carsten Helbing, will lead the initiative.
Although both companies will contribute staff, Rivian will initially provide most personnel.
Rivian received $1 billion through a convertible note at the JV's inception. With the JV now operational, Volkswagen has committed an additional $1.3 billion to Rivian for background IP licenses and a 50% equity stake.
The remaining investment, up to $3.5 billion, will be contingent on achieving specific milestones: $1 billion linked to financial performance, $1.5 billion tied to technical and operational benchmarks, and $1 billion structured as loans with time-based disbursements.
Under the agreement, through 2028, Rivian will cover 25% of shared platform costs, while Volkswagen will handle 75%. Starting in 2029, the partners will split expenses evenly, with Volkswagen providing an extra $100 million annually to reduce Rivian's financial burden.
Rivian expects the capital from Volkswagen and its existing liquidity to be sufficient to support operations through the production ramp of the R2 model in Normal, Illinois, and future midsize platforms in Georgia.
Analyst Delaney views the joint venture as a positive development for Rivian, significantly improving its balance sheet and liquidity without additional stock dilution.
Delaney stated that the deal highlights the strategic value of Rivian's technology platform, particularly in software and services, as emphasized in the recent "Platforms &amp; Power" report.
Despite these positives, the analyst maintains a Neutral rating on Rivian shares, citing a challenging competitive landscape, uncertainties around EV demand, and policy risks in the U.S. market.
Following the announcement, Delaney updated his financial estimates for Rivian, accounting for reduced operating expenses and an adjusted share count balanced against expected equity method losses from the JV.
The revised EPS forecasts, including stock-based compensation (SBC), are—$4.49 for 2024,—$3.10 for 2025, and—$3.00 for 2026, reflecting slight improvements from prior estimates. Excluding SBC, the EPS projections stand at—$3.77 for 2024,—$2.35 for 2025, and—$2.20 for 2026.
The analyst also raised Rivian's 12-month price target, citing improved free cash flow and a stronger balance sheet. The valuation now applies a 2.5x multiple on projected Q5-Q8 revenue, up from the previous 2x multiple.
Wedbush analysts, led by Dan Ives, view Volkswagen's increased $5.8 billion investment in Rivian as a <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41938838/rivians-deal-with-volkswagen-will-help-ev-giant-navigate-the-ship-in-stormy-waters-says-top-analyst-maintains-outperform-rating-with-20-target" rel="noreferrer noopener">pivotal boost for</a> the EV maker. They believe the joint venture marks a crucial step toward stabilizing Rivian's finances and enhancing production capabilities.
The partnership aims to strengthen Rivian's capital position, supporting its software and electrical systems integration.
Analysts expect the additional funding to back the R2 production ramp and development at the Georgia facility while the market remains focused on Rivian's execution and profitability goals for the R1 model.
Price Action: RIVN stock is down 11% at $10.71 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41970826/jd-com-q3-earnings-revenue-beats-forecast-amid-consumer-rebound-highlights-supply-chain-strength-eyes-margin-growth" target="_blank" rel="noreferrer noopener">JD.com Q3 Earnings: Revenue Beats Forecast Amid Consumer Rebound, Highlights Supply Chain Strength, Eyes Margin Growth</a></li>
</ul>
Photo by Tada Images on Shutterstock

Reiteration

Tech

RIVN

VWAGY

Rivian-Volkswagen Deal Strengthens Finances, Yet EV Market Risks Remain: Goldman Sachs

Dillard's shares are trading higher after the company reported better-than-expected Q3 EPS results.

22nd Consecutive Year of Increases&nbsp;
ST. LOUIS, Nov. 14, 2024 /PRNewswire/ -- The board of directors of Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) unanimously agreed to increase the annual common stock dividend to $3.14 per share from $3.02 per share. The $0.12 per share increase brings the quarterly rate to $0.785, an increase of 4.0%.

Dividends

Spire Increases Quarterly Common Stock Dividend From $0.7550 To $0.785 Per Share

Wall Street expects Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) to report $2.19 in earnings per share and $6.95 billion in revenues when the company posts fourth-quarter earnings <a href="https://www.benzinga.com/calendars/earnings?tickers=AMAT" target="_blank" rel="noreferrer noopener">after market hours</a>.
The stock is up 20.48% over the past year and 20.25% year-to-date.
Let&#8217;s look at what the charts indicate for Applied Materials stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/41976138/applied-materials-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Applied Materials Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
<h2 class="wp-block-heading">Applied Materials Technical Setup Ahead Of Q4 Earnings&nbsp;</h2>
Applied Materials stock is currently showing signs of a bearish trend, with the stock trading below its key exponential moving averages (five, 20 and 50-day), indicating continued selling pressure and potential downside. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14114318/Screenshot-2024-11-14-at-10.13.04-PM.png" alt="" class="wp-image-648457" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14114318/Screenshot-2024-11-14-at-10.13.04-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14114318/Screenshot-2024-11-14-at-10.13.04-PM-300x218.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111424&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Applied Materials stock price of $186.07 has fallen below several crucial simple moving averages (eight-day at $188.02, 20-day at $185.92, 50-day at $191 and 200-day at $204.03), each presenting a bearish signal.
The MACD (moving average convergence/divergence) reading of negative 1.65 supports this view, suggesting downside momentum. 
Meanwhile, the RSI at 46.97 indicates AMAT stock is nearing oversold territory, potentially signaling short-term relief. 
However, technical indicators broadly suggest caution for now.
<h2 class="wp-block-heading">Applied Materials See 9% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/AMAT/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Applied Materials stock stands at a Buy currently with a price target of $214.89. The latest analyst ratings from Stifel and Susquehanna give Applied Materials stock an average price target of $203.33, suggesting a potential 9.23% upside.
Price Action: Applied Materials stock was trading at $185.75 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41966815/us-futures-marginally-up-as-investors-process-inflation-data-ahead-of-jerome-powells-speech-on-economy-expert-says-fed-should-continue-recalibrating-to-neutral-on-softer-in">US Futures Marginally Up As Investors Process Inflation Data Ahead Of Jerome Powell&#8217;s Speech On Economy: Expert Says Fed Should &#8216;Continue Recalibrating To Neutral&#8217; On Softer Inflation</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

AMAT

Applied Materials: Bearish Chart Signals Ahead Of Q4 Earnings – 9% Upside In Sight?

The long-awaited boxing match between Mike Tyson and Jake Paul is nearly here, set for Friday Nov. 15 on Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), after being rescheduled from an <a href="https://www.benzinga.com/general/entertainment/24/06/39231357/jake-paul-mike-tyson-boxing-match-set-to-stream-on-netflix-with-new-date">original date in July 2024.</a>
Here's a look at how to watch the big fight, the betting odds and several free prediction contests for sportsbook users.
How to Watch Tyson Vs. Paul: First<a href="https://www.benzinga.com/general/entertainment/24/03/37540711/jake-paul-vs-mike-tyson-coming-to-netflix-biggest-fight-in-history"> announced in March 2024,</a> a fight between Tyson and Paul will take place at AT&amp;T Stadium, home of the NFL's Dallas Cowboys
The boxing match is part of a full lineup of fights that includes three title fights on the undercard.
Netflix subscribers will be able to watch the fight for free with coverage starting live at 8 p.m. ET on Friday, Nov. 15. The start time of the Tyson and Paul fight will be dependent on how long the fights are before it.
For Netflix, the fight is part of the company's larger bets on live events and sports content to help boost subscribers of its ad-free and ad-supported plans. The company <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">ended the most recent quarter </a>with 282.7 million global paid subscribers. Netflix recently said it <a href="https://www.benzinga.com/media/24/11/41915397/netflix-reaches-70-million-users-on-ad-supported-plan-boosts-live-sports-ads">has reached </a>70 million subscribers for its ad-supported plans.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/11/41821069/netflix-stock-hits-all-time-highs-company-confirms-stranger-things-season-5-for-2025">Netflix Stock Hits All-Time Highs, Company Confirms &#8216;Stranger Things&#8217; Season 5 For 2025</a>
The Fight Stats: Friday's main event fight will feature a stark difference between the boxers with Tyson coming in at 58 years old, more than twice the age of Paul, who is 27. In fact, Tyson took part in 47 fights before Paul was even born, according to <a href="https://www.espn.com/boxing/story/_/id/39772221/what-boxing-stats-tell-us-mike-tyson-vs-jake-paul-fight-netflix-friday">ESPN</a>.
Tyson holds a 50-6 career boxing record and is one of the most well-known boxers of all time, known as "the Baddest Man on the Planet" and "Iron Mike."
Paul holds a 10-1 boxing record with his professional career beginning in 2020.
Tyson is recognized as one of the best boxers of all time and was named the No. 1 hardest hitter in heavyweight history by ESPN. Tyson became the youngest heavyweight champion ever at the age of 20, and had a run of 37 consecutive victories during his professional boxing career including 33 wins by knockout.
Tyson&#8217;s last professional boxing bout came in 2005. The boxer also took part in several exhibition matches, including a 2020 match against&nbsp;Roy Jones Jr., which was declared a draw after eight rounds.
Paul's last boxing match came in July of this year with a win to add to his impressive 10-1 record. While Paul lacks the experience of Tyson, he comes into the match as the more recent professional boxer and has a 76-inch to 71-inch reach advantage over Tyson.
Unlike most traditional heavyweight boxing matches, the fight will feature 14-ounce gloves instead of 10-ounce gloves and rounds will be two minutes instead of three minutes in length. The fight is scheduled to go eight rounds, instead of a customary 10 or 12 rounds.
Friday's fight between Tyson and Paul is officially sanctioned as a real fight and not an exhibition match.
Betting Odds, Prediction Markets: Friday's fight will likely see strong betting volume thanks to a larger number of viewers potentially from around the world with the fight on Netflix and not on the more costly pay-per-view option.
Betting odds on sportsbook DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) list Paul as the favorite at odds of -200 and Tyson as the underdog at +160. This means a $100 bet on Paul would pay out a profit of $50 if he wins and a $100 bet on Tyson would pay out a profit of $160 if he wins.
DraftKings lists the fight going under 6.5 rounds at the slight favorite of -120 versus the fight going over 6.5 rounds. A prop on the fight going the distance is at +135 with the fight ending before the end of the eighth round listed at odds of -185.
Here are the betting options of winner and winning method:
<ul>
<li>Paul by KO/TKO/DQ: +150</li>
<li>Paul by Decision: +280</li>
<li>Tyson by KO/TKO/DQ: +250</li>
<li>Tyson by Decision: +950</li>
<li>Draw: +750</li>
</ul>
The betting odds imply that Paul is the favorite to win before the eight rounds are over. Tyson as the underdog is more likely to beat Paul by a knockout, TKO or disqualification than to win by a decision after eight rounds, the odds show.
On prediction market <a href="https://polymarket.com/event/jake-paul-vs-mike-tyson-who-will-win">Polymarket</a>, over $7 million has been wagered on predicting a winner of the boxing match. The odds show Paul as the favorite at 63% and Tyson the underdog at 29% with a draw listed at 11%.
The prediction market, which went viral during the 2024 election, allows users to deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). Winning wagers cash out at $1 per contract.
Free Prediction Contests: While customers on various platforms can bet on the winner outcome, there are several free prediction contests at various sportsbooks.
Betr, a sports betting and sports media company<a href="https://www.benzinga.com/general/sports-betting/24/03/37515466/betr-announces-new-15m-funding-375m-valuation-how-co-founders-jake-paul-joey-levy-plan-to-"> co-founded by Paul</a>, launched a $50,000 free-to-play game for the boxing match.
The game labeled as "Fight Night Picks" is available for new and existing users of the Betr app in applicable states. The winnings will be paid out in Betr Bucks. The game has only five questions with users needing to pick more or less for each question. Contestants who get all five questions correctly will split the $50,000 jackpot.
The questions are:
<ul>
<li>More or less than 0.5 knockouts</li>
<li>More or less than 110.5 seconds for Jake Paul's walkout</li>
<li>More or less than 0.5 callouts by the winner post-fight in the ring</li>
<li>More or less than 0.5 wins for Jake Paul</li>
<li>More or less than 0.5 ears bitten off</li>
</ul>
DraftKings also has a free $25,000 prediction contest for users, which will pay out winnings in DK Dollars. The contest asks questions like who will win, what will be the winning method, how many punches landed by Paul, how many punches landed by Tyson, total rounds over or under 6.5 rounds, which round will the fight end, total knockdowns, will either boxer bleed during the match, will there be fighting after the final bell and who will Paul call out after the fight.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/23/05/32553618/exclusive-betr-is-not-just-a-sports-betting-company-how-jake-paul-leverages-audience-to-lo">EXCLUSIVE: Betr — Jake Paul&#8217;s Vision For More Than &#8216;Just A Sports Betting Company,&#8217; Leveraging Audience For Lower Acquisition Costs</a></li>
</ul>
Photo: Courtesy Netflix

Entertainment

Sports Betting

Sports

$ETH

$MATIC

$USDC

DKNG

NFLX

Paul Vs. Tyson Boxing Match: How To Watch, Betting Odds, What The Stats Say And More

Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) shares are trading higher by 10% to $45.92 in November following Donald Trump's win in the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 presidential election</a>, as investors expect that his policies will create a favorable environment for financial institutions. 
Trump's plans to expand on the 2017 Tax Cuts and Jobs Act, potentially lowering corporate tax rates further, would increase Bank of America's profitability. 
Reduced taxes allow the bank to retain more of its earnings, which can then be directed toward expanding lending, enhancing shareholder returns or investing in new financial products.
What To Know: Deregulation is another factor that could benefit Bank of America under Trump's leadership. Trump has previously advocated for loosening financial regulations, particularly those imposed by the Dodd-Frank Act, which would give Bank of America more operational flexibility and reduce compliance costs. 
Regulatory relief could support the bank's lending activities, making it easier to extend loans to both consumers and businesses. This is especially advantageous for Bank of America, one of the largest lenders in the U.S., as relaxed regulations could foster growth in its retail and commercial lending segments.
Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a>
What Else: Trump's policies on trade and infrastructure investment are also likely to impact Bank of America positively. As the administration emphasizes economic growth through trade incentives and substantial infrastructure spending, demand for credit may increase as businesses look to finance expansions and infrastructure projects. 
For Bank of America, this could mean greater loan demand and increased fee income from advisory and investment banking services.
Finally, Trump's economic approach may lead to inflationary pressures, which could keep interest rates elevated. Higher rates would improve Bank of America's net interest margin, boosting earnings from loans. 
Altogether, Trump's tax, regulatory, and economic policies provide a positive outlook for Bank of America's growth and profitability, driving investor optimism in the stock following the election.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">Golden Years For M&amp;A Deals Ahead Under Trump? Analysts Highlight Top 10 Large-Cap Candidates</a>
<h2 class="wp-block-heading">How To Buy BAC Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bank of America&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BAC has a 52-week high of $46.52 and a 52-week low of $29.20.

What's Going On With Bank Of America (BAC) Shares

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has soared since Donald Trump won the 2024 presidential election and Benzinga readers think that the momentum could carry into 2025 for the<a href="https://www.benzinga.com/news/management/24/11/41856784/elon-musks-wealth-tops-300-billion-as-teslas-market-cap-soars-above-1-trillion"> electric vehicle company.</a>
What Happened: Tesla CEO Elon Musk endorsed Trump for president in the 2024 election and helped campaign for his victory. While the move may have been risky, given Trump's past criticism of electric vehicles, it appears to have paid off for Tesla's stock price and analysts' <a href="https://www.benzinga.com/markets/24/11/41890944/tesla-the-most-undervalued-ai-name-in-the-market-in-our-view-says-dan-ives-trumps-win-a-game-changer">optimism for the future.</a>
Tesla stock closed at $251.44 on Nov. 5, the day of the 2024 presidential election. With Trump being declared the victor in the early morning hours, the stock opened at $284.67 on Nov. 6 and closed the day trading at $288.53, up 14.8%.
The stock was volatile in the after-hours trading markets and overnight trading market hours for brokers offering customers the option.
Since Election Day, the stock is up 29.2%, posting the majority of its +32.4% year-to-date gains over the last two weeks.
Benzinga recently polled readers to see if the momentum can continue and carry Tesla to new all-time highs.
"Will Trump and Musk's close ties help drive Tesla to new all-time highs in 2025?" Benzinga asked.
The results were:
<ul>
<li>Yes: 62%</li>
<li>No: 14%</li>
<li>Yes, Tesla will reach all-time high in 2025, but not because of Musk/Trump friendship: 24%</li>
</ul>
The poll found that the majority of readers think the friendship between Musk and Trump will take Tesla stock to all-time highs in 2025. Twenty-four percent of poll respondents think Tesla stock will hit all-time highs in 2025, but not due to Trump.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111424">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The biggest takeaway from the poll is that whether or not it's because of Trump and Musk being friends, 86% of readers believe Tesla stock will hit all-time highs in 2025.
The current all-time high for Tesla stock is $414.50, hit on Nov. 7, 2021. To reach the all-time high, which last occurred three years ago, Tesla stock would have to gain an additional 27.6% from today's share price of $324.96.
Trump has spoken negatively about electric vehicles many times in the past, and many believe that he will remove federal credits for American buyers of EVs.
While the ending of federal credits for consumers could hurt the overall electric vehicle sector, analysts see the move having a lower impact on Tesla due to its profitability and scale. Instead, the move could hurt Tesla's competition and improve the company's market share in the sector.
One item to watch is if Trump reverses course in his comments that he <a href="https://www.benzinga.com/general/politics/24/10/41298125/maybe-musk-missed-the-memo-trumps-plan-to-ban-autonomous-vehicles-could-sour-friendship">will ban autonomous vehicles</a> from the road. Trump recently made those comments around the same time that Tesla showed off its Cybercab at its We Robot event in California.
Tesla is betting big on robotaxis, and a government that isn't friendly toward the vehicles could harm Tesla's stock price and future growth.
Musk's friendship with Trump could also help his other companies, like social media platform X and space company SpaceX. While this won't be a positive for Tesla, it could help with Musk's companies overall and perhaps trickle down to brand awareness for Tesla and a more favorable environment for Musk in the United States overall.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41958626/tesla-short-sellers-down-8-billion-since-2024-election-and-there-could-be-more-pain-ahead">Tesla Short Sellers Down $8 Billion Since 2024 Election — And There Could Be More Pain Ahead</a></li>
</ul>
The study was conducted by Benzinga from Nov. 6 through Nov. 7, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 112 adults.
Image created using artificial intelligence via Midjourney.

Politics

Exclusives

TSLA

If Tesla Stock Hits All-Time Highs In 2025, Will It Be Driven By Trump-Musk Relationship? Benzinga Readers Say This

Vermont-based ice cream manufacturer Ben &amp; Jerry&#8217;s, an independent subsidiary of Unilever plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>), has a long <a href="https://www.benzinga.com/markets/cannabis/24/04/38440644/ben-jerrys-wont-stop-fighting-until-theres-cannabis-legalization-and-justice-says-activism-lead">history of corporate activism</a>. Its latest round has brought it into conflict with its own parent company.
What Happened: On Wednesday, Ben &amp; Jerry&#8217;s filed a contract lawsuit against Unilever in the Southern District of New York. The federal lawsuit alleges that Unilever breached Ben &amp; Jerry&#8217;s autonomy over social justice activism, specifically its various statements in support of a cease-fire between the Israeli government and Hamas in <a href="https://www.benzinga.com/markets/asia/24/10/41405272/sinwar-death-marks-turning-point-in-gaza-war-netanyahu-says-its-the-beginning-of-the-end">the ongoing war</a>. Ben &amp; Jerry&#8217;s and Unilever hold agreements to allow the brand's independent board to make social justice activism decisions.
Unilever has not yet filed a response, but a spokesperson reacted to Ben &amp; Jerry&#8217;s lawsuit in an email to Benzinga.
&#8220;Our heart goes out to all victims of the tragic events in the Middle East,&#8221; the spokesperson said. &#8220;We reject the claims made by B&amp;J's social mission board, and we will defend our case very strongly. We would not comment further on this legal matter."
The Burlington-based company&#8217;s complaint alleges that Unilever &#8220;silenced&#8221; efforts to speak out in support of Palestine. Following Ben &amp; Jerry&#8217;s statement in 2023 in support of an Israel-Palestinian cease-fire, the London, England-based parent company allegedly threatened to dissolve its independent board and sue board members.
In addition, Unilever blocked Ben &amp; Jerry&#8217;s donations to Jewish Voice for Peace and the Council on American-Islamic Relations, two organizations in support of Palestinians, the ice cream brand alleges. 
Ben &amp; Jerry&#8217;s previously sued Unilever in 2022. The ice cream manufacturer had announced a <a href="https://www.benzinga.com/government/21/07/22048169/ben-jerrys-joins-bds-movement-to-boycott-west-bank-and-east-jerusalem">cessation of sales</a> in the occupied West Bank and East Jerusalem in protest of Israeli policy. Unilever subsequently sold Ben &amp; Jerry&#8217;s Israel license, something Ben &amp; Jerry&#8217;s said was done without permission.
Why It Matters: It is considered rare for a subsidiary to file a lawsuit against its own parent company.
<a href="https://www.wsj.com/business/unilever-plans-to-spin-off-ice-cream-unit-in-shake-up-affecting-7-500-jobs-c768e45f?mod=article_inline">According</a> to the Wall Street Journal, Unilever has considered selling off its ice cream brands, including Ben &amp; Jerry&#8217;s, Breyer&#8217;s and Popsicle. Unilever acquired Ben &amp; Jerry&#8217;s in 2000.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">Golden Years For M&amp;A Deals Ahead Under Trump? Analysts Highlight Top 10 Large-Cap Candidates</a></li>
</ul>
Photo via Shutterstock.

Legal

Ben & Jerry's Sues Parent Company Unilever Over Alleged Gaza Protest Censorship

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 41%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $381,093, and 5 are calls, for a total amount of $293,373.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $22.5 and $65.0 for Moderna, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1677.71 with a total volume of 5,741.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $22.5 to $65.0 over the last 30 days.
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731611773_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.8</td>
<td>$22.25</td>
<td>$22.6</td>
<td>$22.50</td>
<td>$113.0K</td>
<td>2</td>
<td>50</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.96</td>
<td>$2.91</td>
<td>$2.96</td>
<td>$35.00</td>
<td>$73.1K</td>
<td>2.1K</td>
<td>363</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$0.84</td>
<td>$0.7</td>
<td>$0.84</td>
<td>$41.00</td>
<td>$65.5K</td>
<td>4.2K</td>
<td>2.0K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$7.95</td>
<td>$7.8</td>
<td>$7.9</td>
<td>$40.00</td>
<td>$61.6K</td>
<td>180</td>
<td>132</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.19</td>
<td>$1.09</td>
<td>$1.18</td>
<td>$41.00</td>
<td>$61.3K</td>
<td>4.2K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,268,882, the price of MRNA is down by -1.86%, reaching $41.35.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 98 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

MRNA

Moderna's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AFRM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Affirm Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 21%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $673,247, and 10 are calls, for a total amount of $1,814,684.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $85.0 for Affirm Holdings during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Affirm Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Affirm Holdings's substantial trades, within a strike price spectrum from $40.0 to $85.0 over the preceding 30 days.
<h3>Affirm Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731611768_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.71</td>
<td>$50.00</td>
<td>$1.2M</td>
<td>2.5K</td>
<td>2.2K</td>
</tr>
<tr>
<td>AFRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$50.00</td>
<td>$518.5K</td>
<td>2.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$15.5</td>
<td>$14.6</td>
<td>$15.08</td>
<td>$40.00</td>
<td>$150.8K</td>
<td>2.0K</td>
<td>100</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$17.1</td>
<td>$15.9</td>
<td>$16.75</td>
<td>$50.00</td>
<td>$134.0K</td>
<td>2.4K</td>
<td>112</td>
</tr>
<tr>
<td>AFRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.49</td>
<td>$0.48</td>
<td>$0.48</td>
<td>$52.50</td>
<td>$67.0K</td>
<td>2.0K</td>
<td>1.9K</td>
</tr>
</tbody>
</table>

<h3>About Affirm Holdings</h3>
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.
Following our analysis of the options activities associated with Affirm Holdings, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Affirm Holdings</h3>
<ul>
<li>Currently trading with a volume of 5,482,048, the AFRM's price is down by -2.06%, now at $53.69. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 84 days.</li>
</ul>
<h3>Expert Opinions on Affirm Holdings</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $56.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on Affirm Holdings with a target price of $57. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Affirm Holdings, which currently sits at a price target of $55. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Affirm Holdings, which currently sits at a price target of $56. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Affirm Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

AFRM

Market Whales and Their Recent Bets on AFRM Options

Investors with a lot of money to spend have taken a bullish stance on Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with UPST, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Upstart Hldgs.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $139,970, and 6 are calls, for a total amount of $316,748.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $80.0 for Upstart Hldgs over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Upstart Hldgs options trades today is 1367.62 with a total volume of 1,958.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Upstart Hldgs's big money trades within a strike price range of $45.0 to $80.0 over the last 30 days.
<h3>Upstart Hldgs 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731611763_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$23.1</td>
<td>$22.25</td>
<td>$23.01</td>
<td>$45.00</td>
<td>$92.0K</td>
<td>1.0K</td>
<td align="right">41</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.23</td>
<td>$2.07</td>
<td>$2.23</td>
<td>$65.00</td>
<td>$62.4K</td>
<td>2.3K</td>
<td align="right">458</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$3.25</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$67.00</td>
<td>$58.6K</td>
<td>136</td>
<td align="right">244</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$20.35</td>
<td>$19.45</td>
<td>$19.81</td>
<td>$65.00</td>
<td>$49.5K</td>
<td>271</td>
<td align="right">25</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.23</td>
<td>$2.22</td>
<td>$2.23</td>
<td>$65.00</td>
<td>$45.7K</td>
<td>2.3K</td>
<td align="right">668</td>
</tr>
</tbody>
</table>

<h3>About Upstart Hldgs</h3>
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.
Following our analysis of the options activities associated with Upstart Hldgs, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Upstart Hldgs</h3>
<ul>
<li>Currently trading with a volume of 3,381,222, the UPST's price is down by -1.62%, now at $66.7. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 89 days.</li>
</ul>
<h3>Professional Analyst Ratings for Upstart Hldgs</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $66.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler has elevated its stance to Overweight, setting a new price target at $85. 
&#x2A; An analyst from JP Morgan upgraded its action to Neutral with a price target of $45. 
&#x2A; An analyst from Wedbush persists with their Neutral rating on Upstart Hldgs, maintaining a target price of $60. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Upstart Hldgs with a target price of $56. 
&#x2A; An analyst from Citigroup upgraded its action to Buy with a price target of $87. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Upstart Hldgs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

UPST

Check Out What Whales Are Doing With UPST

Evotec Shares Resume Trade

Gaxos.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) shares are moving higher Thursday after the company&#8217;s board approved the purchase of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as a <a href="https://www.benzinga.com/pressreleases/24/11/g41968875/gaxos-board-of-directors-approves-bitcoin-as-treasury-reserve-asset">treasury reserve asset</a>.
The Details: Gaxos.AI, an AI applications company, said its board of directors approved the purchase of up to $1 million in Bitcoin.
&#8220;As demand for Bitcoin grows and so does its acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset,&#8221; said Vadim Mats, CEO of Gaxos. 
&#8220;With recent approval of Bitcoin ETFs and growing support from institutional investors, it is a great addition to our treasury strategy. Its limited supply and inflation-resistant characteristics provide a functional store of value.&#8221;&nbsp;
The strategic move from Gaxos comes after <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41887406/bitcoin-shatters-87000-all-time-high-ethereum-up-5-dogecoin-blasts-through-0-30-for-20-gain-in-memorable-monday-trading-session">Bitcoin</a> soared to new all-time highs earlier this week. Bitcoin was trading around $89,000 at the time of writing, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
<h3 class="wp-block-heading">Is GXAI A Good Stock To Buy?</h3>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/GXAI">Gaxos.AI</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Gaxos.AI does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/GXAI">Gaxos.AI</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/41945626/whats-going-on-with-bitcoin-mining-stocks-mara-holdings-riot-platforms-and-cleanspark">What&#8217;s Going On With Bitcoin Mining Stocks MARA Holdings, Riot Platforms And CleanSpark?</a>
GXAI Price Action: At the time of publication, Gaxos.AI shares were up 11.1% at 1.61, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Unsplash

$BTC

GXAI

What's Going On With Gaxos.AI Stock Thursday?

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling by more than 150 points on Thursday.
The Dow traded down 0.38% to 43,790.84 while the NASDAQ fell 0.34% to 19,166.29. The S&amp;P 500 also fell, dropping, 0.37% to 5,963.37.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a>
Leading and Lagging Sectors Information technology shares rose by 0.2% on Thursday.
In trading on Thursday, industrials shares fell by 1.4%.
Top Headline
U.S. crude oil inventories increased by 2.089 million barrels in the week ended Nov. 8, compared to market estimates of a 1.85 million gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>AgEagle Aerial Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>) shares shot up 129% to $3.68 after the company announced 17 new purchase orders for its eBee TAC drones from U.S. defense and security customers.</li>
<li>Shares of DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) got a boost, surging 16% to $10.48 after the company reported better-than-expected third-quarter revenue results.</li>
<li>AC Immune SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) shares were also up, gaining 20% to $3.7503 after the company announced interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056 for the treatment of patients with early Parkinson's disease.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Nuvectis Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares dropped 40% to $6.35 after the company reported data from its Phase 1b study evaluating NXP800.</li>
<li>Shares of Sow Good Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOWG#NASDAQ">SOWG</a>) were down 58% to $4.1099 after the company reported worse-than-expected quarterly financial results.</li>
<li>Vislink Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VISL#NASDAQ">VISL</a>) was down, falling 32% to $4.4535 after the company reported worse-than-expected third-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $68.41 while gold traded down 0.4% at $2,575.60.
Silver traded down 0.4% to $30.555 on Thursday, while copper fell 0.2% to $4.0750.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.08%, Germany's DAX climbed 1.37% and France's CAC 40 gained 1.32%. Spain's IBEX 35 Index gained 1.29%, while London's FTSE 100 rose 0.51%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.48%, Hong Kong's Hang Seng Index falling 1.96%, China's Shanghai Composite Index dipping 1.73% and India's BSE Sensex falling 0.14%.
Economics
<ul>
<li>U.S. initial jobless claims declined by 4,000 from the previous week to 217,000 in the week ending Nov. 9, compared to market estimates of 223,000.</li>
<li>U.S. producer prices rose 0.2% month-over-month in October compared to a revised 0.1% gain in September and in-line with market expectations.</li>
<li>U.S. crude oil inventories increased by 2.089 million barrels in the week ended Nov. 8, compared to market estimates of a 1.85 million gain.</li>
</ul>
Now Read This: 
<ul>
<li>N<a href="https://www.benzinga.com/24/11/41971143/nvidia-to-rally-around-23-here-are-10-top-analyst-forecasts-for-thursday">vidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

ACIU

NVCT

SOWG

UAVS

VISL

S&P 500 Moves Lower; US Crude Oil Inventories Increase

<a href="https://truthsocial.com/@realDonaldTrump/posts/113482854385986466" title="https://truthsocial.com/@realDonaldTrump/posts/113482854385986466">https://truthsocial.com/@realDonaldTrump/posts/113482854385986466</a>

Macro Economic Events

Economics

Donald J. Trump Posts On Truth "I respect Jamie Dimon, of JPMorgan Chase, greatly, but he will not be invited to be a part of the Trump Administration. I thank Jamie for his outstanding service to our Country!"

Legendary investor Ken Fisher's hedge fund, Fisher Asset Management, grew the value of its portfolio by more than $14 billion dollars <a href="https://www.benzinga.com/personal-finance/24/09/41030896/why-ken-fisher-says-capital-preservation-could-cost-you-big-in-retirement">in the last quarter</a>.
Here's a look at the fund's most significant trades.  
Top Holdings: Fisher Asset Management reported approximately $244 billion in assets under management (AUM), according to an SEC<a href="https://www.sec.gov/Archives/edgar/data/850529/000085052924000012/xslForm13F_X02/primary_doc.xml"> filing</a>. 
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
The firm also added small amounts to each of its top five positions: 
<ul>
<li>Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and </li>
<li>Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>). </li>
</ul>
Top Buys: Fisher Asset Management's top buy in terms of value was $2.09 billion in shares of the iShares 7-10 Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEF#NASDAQ">IEF</a>) which provides targeted exposure to U.S. Treasury bonds with remaining maturities between seven and ten years. Treasury bonds are generally considered low-risk investments, which can help balance riskier assets in a diversified portfolio. 
The fund's second and third-largest buys were $850 million in shares of JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and $490 million worth of shares of oil and natural gas producer ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>). 
Top Sells: The hedge fund's top sells by value were $1.35 billion in shares of the iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LQD#NYSE">LQD</a>), $750 million worth of Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) shares and $710 million in shares of Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>). 
New Holdings: One of the fund's most notable new holdings is Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), a digital banking services provider also backed by Warren Buffett. Fisher Asset management opened a position in Nu Holdings with approximately 7.23 million shares valued at more than $98.7 million.&nbsp;
The hedge fund also took a $28.3 million new position in wealth manager UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) and opened a $17.2 million position in the iShares MSCI China A ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CNYA#BATS">CNYA</a>), which tracks an index composed of Chinese equities available to international investors.
Why It Matters: Hedge funds often use sophisticated investment strategies and have access to extensive research which can provide insights into emerging market trends. Individual investors can track hedge funds for investment ideas, successful strategies or compare their own performance against professional investors.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock

AAPL

AMZN

CNYA

GOOGL

iShares Trust Barclays 7-10 Year Treasury Bond Fund

MSFT

NVDA

Here's How Billionaire Ken Fisher's Hedge Fund Made $14 Billion Last Quarter

Evotec Shares Halted To The Upside; Stock Now 10.33%

HALO

Evotec Is Said To Attract Takeover Interest From Halozyme

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), retaining the price target of $5...

Buy Rating Affirmed for VYNE Therapeutics on Strong Financials and Promising Drug Trials

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on VYNE Therapeutics (VYNE – Research Report). The associated price targe...

Buy Rating for VYNE Therapeutics Amid Strong Financial Footing and Promising Clinical Trials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
VYNE Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vyne-stock-quote/">VYNE</a>) just reported results for the second quarter of 2024.<ul><li>VYNE Therapeutics reported earnings per share of -22 cents. This was below the analyst estimate for EPS of -19 cents.</li><li>The company reported revenue of $198,000.</li><li>This was 80% better than the analyst estimate for revenue of $110,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vyne-stock-earnings-vyne-therapeutics-for-q2-of-2024/">VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024

VYNE Therapeutics GAAP EPS of -$0.22 beats by $0.01, revenue of $0.2M beats by $0.09M

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.7...

Buy Rating Affirmed for VYNE Therapeutics Amid Promising Early Data for VYN202

VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from...

Buy Rating for VYNE Therapeutics Backed by Promising Early Phase Results and Strong Clinical Development Trajectory

Reports Q3 revenue $121,000 vs $114,000 last year. "We continue to make excellent progress in advancing our two InhiBET(TM) clinical programs VYN20...

VYNE Therapeutics reports Q3 EPS (29c) vs ($2.01) last year

VYNE Therapeutics GAAP EPS of -$0.29, revenue of $0.1M

VYNE Therapeutics: Promising Clinical Progress and Financial Stability Support Buy Rating

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) and keeping the price target at $6...

VYNE Therapeutics: Robust Pipeline and Financial Stability Underpin Buy Rating

Press Releases

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

Health Care

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Management

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics to Participate in September Investor Conferences

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Comments

VYNE Therapeutics

VYNE Therapeutics (VYNE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga